GeneDx Holdings Corp. — Director's Dealing 2021

Jul 27, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Sema4 Holdings Corp. (SMFR)
CIK: 0001818331
Period of Report: 2021-07-22

Reporting Person: Schadt Eric (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-22	Employee Stock Option (Right to Buy)	$0.1529	A	2564847	Acquired	2027-05-31	Class A Common Stock (2564847)	Direct
2021-07-22	Employee Stock Option (Right to Buy)	$0.1529	A	2264674	Acquired	2027-05-31	Class A Common Stock (2264674)	Direct
2021-07-22	Employee Stock Option (Right to Buy)	$0.7659	A	401699	Acquired	2029-10-16	Class A Common Stock (401699)	Direct
2021-07-22	Employee Stock Option (Right to Buy)	$0.7659	A	960472	Acquired	2029-10-16	Class A Common Stock (960472)	Direct
2021-07-22	Employee Stock Option (Right to Buy)	$0.7659	A	2311488	Acquired	2030-02-17	Class A Common Stock (2311488)	Direct

Footnotes

F1: This option is fully vested.

F2: Pursuant to the business combination between the Issuer (which was formerly known as CM Life Sciences, Inc.) and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), each share of Sema4 outstanding common stock was automatically converted into the right to shares of the Issuer's Class A Common Stock based on a 1 to 123.8338 exchange ratio ("Exchange Ratio"). In addition, each outstanding Sema4 equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the Sema4 equity awards.

F3: 6.25% of the total shares underlying the option vest in quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.